 |
|
Ocular Adverse Effects Associated With Cyclooxygenase-2 Inhibitors
Arch Ophthalmol. 2006;124:277-279.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
An important event in the treatment of inflammatory disease was the identification of selective inhibitors of cyclooxygenase-2 (COX-2). Cyclooxygenase-1 (COX-1) inhibitors are responsible for many of the adverse effects of nonsteroidal anti-inflammatory drugs, such as gastrointestinal disturbances, while blockage of COX-2 mediates the anti-inflammatory activity with fewer adverse effects. Selective COX-2 inhibitors include rofecoxib (Vioxx; Merck & Co, West Point, Pa), celecoxib (Celebrex; Pfizer Inc, New York, NY), valdecoxib (Bextra; Pfizer Inc), and lumiracoxib (Prexige; Novartis Pharmaceuticals Corp, Basel, Switzerland). Nimesulide (Ainex; Schering-Plough, Santiago, Chile) (and other trade names), and etolodac (Lodine; Wyeth, Madison, NJ) also exhibit selective COX-2 inhibition and can be included in this class of medication which is used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, and dysmenorrhea.1 Nimesulide and lumiracoxib are not approved by the Food and Drug Administration and are not marketed in the United States and Merck removed Vioxx from the market . . . [Full Text of this Article]Methods
Results
Conclusions
AUTHOR INFORMATION
Frederick W. Fraunfelder, MD;
Jonathan Solomon, MD;
Thomas J. Mehelas, MD
RELATED LETTERS
Adverse Effects of Cyclooxygenase-2 Inhibitors on Ocular Vision
Carsten H. Meyer, Stefan Mennel, Jörg C. Schmidt, and Peter Kroll
Arch Ophthalmol. 2006;124(9):1368.
EXTRACT
| FULL TEXT
Adverse Effects of Cyclooxygenase-2 Inhibitors on Ocular Vision—Reply
Frederick W. Fraunfelder
Arch Ophthalmol. 2006;124(9):1368.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Adverse effects of cyclooxygenase-2 inhibitors on ocular vision.
Meyer et al.
Arch Ophthalmol 2006;124:1368-1368.
FULL TEXT
|
